Tele: 561.316.3330
Breaking Medical Device News

Wednesday, October 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeNON PROFITMTF Biologics Wound Care Tissue Forms Now Accessible to Over 240 Million...

MTF Biologics Wound Care Tissue Forms Now Accessible to Over 240 Million Americans

June 22, 2020

MTF Biologics, a global nonprofit organization that saves and heals lives through advancing tissue and organ donation, transplantation, and research, today announced that new positive coverage decisions by Aetna, Centene Corporation, WellCare and Tufts Health Plan will provide greater access to its human placental and dermal allografts, AmnioBand® and AlloPatch®, for the treatment of diabetic foot ulcers (DFUs).

In revising their coverage, Aetna, one of the largest commercial health insurance plans in the nation with over 22 million members, as well as Centene, WellCare, and Tufts Health Plan, join the likes of Anthem®, Cigna®, regional health insurance plans including all Blue Cross® and Blue Shield® plans, Medicare, and a number of state Medicaid programs in providing access to these tissue forms to over 240 million Americans.

This sweeping expansion of coverage means that even more Americans who are suffering with complex and chronic wounds, such as DFUs, will have access to these safe, clinically proven and cost-effective human allograft treatment options. This wider coverage is especially critical today as Americans are facing more health and economic challenges due to the COVID-19 pandemic.

Published studies have shown that these high-quality tissue forms have some of the lowest cost to closure rates and better outcomes when compared to other tissues on the market — aligning with our nation’s move from a fee-for-service to a value-based health care delivery and reimbursement model.

“Our patients are our first priority at MTF Biologics, and we are determined that Americans who are suffering with complex and chronic wounds have access to our allograft solutions to help them recover and heal,” said Joe Yaccarino, President and CEO of MTF Biologics. “Today 34 million Americans suffer from diabetes and one in four of them will likely develop a diabetic foot ulcer. In this time of health and economic uncertainty, the last thing they should be concerned about is access to treatment. This recent expansion of coverage furthers our mission of honoring the gift of donation by ensuring that our vital wound care allografts are available to Americans who need them.”

The AmnioBand innovative family of placental allografts and the AlloPatch dermal based technologies can be used to treat a variety of complex and chronic wounds, such as DFUs, venous leg ulcers and decubitus ulcers. The AmnioBand placental family of solutions are minimally processed human placental allografts that retain the structural properties of an extracellular matrix, serving as a premier wound covering for complex and chronic wounds. AlloPatch Pliable is a pliable human reticular dermal matrix, providing a framework for cellular repopulation and vascularization at the surgical site.

“MTF Biologics is committed to providing innovative, effective wound care tissue forms to the patients who need them,” said Kim Rounds, MTF Biologics Vice President of Wound Care. “Our team of clinicians and scientists have worked for years to develop allograft solutions that save and heal lives and to publish the robust clinical evidence needed to gain broad insurance coverage. We are proud, that with these recent coverage decisions, now over 240 million Americans have access to our life-changing human allografts.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Luciana Borio MD is a respected physician with vast experience in advancing major regulatory and policy agendas for the United States.

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy